Co-DiagnosticsHAM:C970 63 Pretax Margin % is -6,274.60% as of Mar. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €3.88. The stock has 6 warning signs investors should review. Among 818 Medical Devices & Instruments companies, Co-Diagnostics ranks worse than 97.56% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Co-Diagnostics's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-7.91 Mil. Co-Diagnostics's Revenue for the
three
months ended in Mar. 2026 was €0.13 Mil. Therefore, Co-Diagnostics's pretax margin for the quarter that ended in Mar. 2026 was -6,274.60%.
The historical rank and industry rank for Co-Diagnostics's Pretax Margin % or its related term are showing as below:
HAM:C970'
s Pretax Margin % Range Over the Past 10 Years
Min: -86987.5 Med: -959.95 Max: 57.1
Current: -6981.89
HAM:C970's Pretax Margin % is ranked worse than 97.56% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.505
vs HAM:C970: -6981.89
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Co-Diagnostics Pretax Margin % Related Terms
Co-Diagnostics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Co-Diagnostics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:C970 vs CTSO, NMTC, RDGL: Pretax Margin % Comparison
For the Medical Devices subindustry, Co-Diagnostics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics (HAM:C970) has a Pretax Margin % of -6,274.60% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Co-Diagnostics and its competitors. According to the industry distribution chart, Co-Diagnostics ranks #798 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 97.6%.
Is Co-Diagnostics' Pretax Margin % too high?
Co-Diagnostics' current Pretax Margin % is -6,274.60%. Based on the distribution chart, Co-Diagnostics ranks #798 out of 818 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Pretax Margin % compare to CTSO and NMTC?
According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #798 out of 818 companies for Pretax Margin %. This places Co-Diagnostics in the lower half of its industry. The industry median Pretax Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.51, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Co-Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Co-Diagnostics's current Pretax Margin % is -6,274.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Pretax Margin % of -6,274.60%. The stock's GF Value™ is €3.88, compared to a current price of €5.55 — trading 43% above its estimated fair value. The current Pretax Margin % is -6,274.60%. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Pretax Margin % is -6,274.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued.
The current stock price of €5.55 is trading 43% above its estimated GF Value™ of €3.88.
Key valuation signals for HAM:C970:
Pretax Margin %: -6,274.60%
GF Value™: €3.88 vs. price of €5.55 (43% above fair value)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score
Get the complete analysis for HAM:C970
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
